Fusion startup Commonwealth Fusion Systems may go public in a few years
Commonwealth Fusion Systems (CFS), the best-funded fusion startup with $4 billion raised, could pursue an initial public offering within the next two to three years, based on industry sources and the recent appointment of a CFO with IPO experience.

Commonwealth Fusion Systems (CFS) is the most well-funded fusion energy startup, having raised $4 billion over seven years, including a recent $1 billion injection. Sources and developments suggest the company may go public in the next two or three years, according to TechCrunch.
New CFO with biotech background
CFS recently appointed Lorence Kim as its Chief Financial Officer. Kim previously served as CFO at Moderna, where he helped take the biotech company public in 2018. He sees parallels between fusion today and mRNA a decade ago: scientifically proven but commercially unproven. Christine Dunn, CFS head of communications, noted that Kim's experience is valuable for bringing a novel product to market. However, she stated that Kim's arrival does not necessarily mean IPO preparations have begun.
Progress on Sparc and Arc reactors
CFS is advancing its demonstration reactor, Sparc, initially expected by 2025 but now targeted for launch later this year. The company hopes Sparc will achieve scientific breakeven next year, meaning it produces more energy than it consumes. Meanwhile, work has started on the commercial-scale power plant Arc, located in Chesterfield County, Virginia, with permits underway and operations expected in the early 2030s. Google has already agreed to purchase half of Arc's output.
Market opportunities
Other fusion companies are also moving toward public markets: General Fusion went public via SPAC recently, and TAE Technologies plans to merge with Trump Media and Technology Group. The booming AI data center sector is driving huge electricity demand, which CFS aims to capitalize on. Kim's experience managing Moderna's finances during its early loss-making years as a public company could prove valuable as CFS faces heavy expenditures ahead.


